Overview Financials News + Filings Key Docs Charts Ownership Insiders
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
Tags Quarterly results Appointed director CC transcript
|
BIOCRYST PHARMACEUTICALS INC (BCRX)
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
04/07/2021 |
GN
| BioCryst to Present at 20th Annual Needham Virtual Healthcare Conference |
03/19/2021 |
GN
| BioCryst Appoints Helen Thackray, M.D., as Chief Research and Development Officer |
02/25/2021 |
GN
| BioCryst Receives Positive CHMP Opinion for ORLADEYO™ (berotralstat), an Oral, Once-daily Therapy to Prevent Attacks in Patients with Hereditary Angioedema |
02/09/2021 |
GN
| BioCryst to Present Data at 2021 American Academy of Allergy, Asthma & Immunology Annual Meeting |
02/03/2021 |
GN
| BioCryst Announces FDA Approval of Supplemental New Drug Application for RAPIVAB® Expanding Patient Population to Include Children Six Months and Older |
01/22/2021 |
GN
| BioCryst Announces Approval of ORLADEYO™ (berotralstat) in Japan for the Prophylactic Treatment of Hereditary Angioedema |
01/07/2021 |
GN
| BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
01/06/2021 |
GN
| BioCryst to Present at 39th Annual J.P. Morgan Healthcare Conference |
12/22/2020 |
GN
| BioCryst Provides Update on Galidesivir Program |
12/21/2020 |
GN
| BioCryst Announces Positive Phase 1 Results with BCX9250, an Oral ALK-2 Inhibitor for Treatment of Fibrodysplasia Ossificans Progressiva |
12/16/2020 |
GN
| BioCryst Announces U.S. Availability of ORLADEYO™ (berotralstat) for the Treatment of Hereditary Angioedema |
12/11/2020 |
GN
| BioCryst to Present at JMP Securities Hematology Summit |
12/07/2020 |
GN
| Royalty Pharma Acquires Royalty Interest in ORLADEYO and BCX9930 From BioCryst Pharmaceuticals |
12/07/2020 |
GN
| BioCryst Announces $325 Million of Funding from Royalty Pharma and Athyrium Capital Management |
12/06/2020 |
GN
| BioCryst's Oral Factor D Inhibitor (BCX9930) Shows High Potency and Specificity for Alternative Pathway of Complement |
12/03/2020 |
GN
| BioCryst Announces FDA Approval of ORLADEYO™ (berotralstat), First Oral, Once-daily Therapy to Prevent Attacks in Hereditary Angioedema Patients |
12/01/2020 |
GN
| BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
11/20/2020 |
GN
| BioCryst to Present at Upcoming Virtual Investment Conferences |
11/13/2020 |
GN
| BioCryst Presents Data Showing Sustained Attack Rate Reductions, Improved Patient Satisfaction and Quality of Life for HAE Patients Taking Berotralstat in APeX-2 Trial |
11/12/2020 |
GN
| BioCryst to Present Data at the 2020 ASH Annual Meeting |
11/02/2020 |
GN
| BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
10/30/2020 |
GN
| MHRA Grants HAE Patients Early Access to BioCryst's Berotralstat in United Kingdom |
10/22/2020 |
GN
| BioCryst to Report Third Quarter 2020 Financial Results on November 5 |
10/05/2020 |
GN
| BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
09/30/2020 |
GN
| BioCryst's Oral Factor D Inhibitor, BCX9930, Shows Clinical Benefit as Monotherapy Through 400 mg bid in Treatment-naïve PNH Patients |
09/03/2020 |
GN
| BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
08/31/2020 |
GN
| NIAID Awards BioCryst New $44 Million Contract to Advance Development of Galidesivir |
08/31/2020 |
GN
| FDA Grants Orphan Drug Designation for BCX9930 in PNH |
08/06/2020 |
GN
| BioCryst Reports Second Quarter 2020 Financial Results and Upcoming Key Milestones |
08/04/2020 |
GN
| BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
07/23/2020 |
GN
| BioCryst to Report Second Quarter 2020 Financial Results on August 6 |
07/02/2020 |
GN
| BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
06/10/2020 |
GN
| Galidesivir Stops Zika Viral Replication in Primate Model |
06/06/2020 |
GN
| Hereditary Angioedema Patients Report Breakthrough Attacks on Current Injectable/Infused Prophylaxis Medication |
|
|
|